Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pollen allergen Phl p 5 from *Phleum pratense* (timothy grass) is a major respiratory allergen recognized by IgE antibodies in 65-90% of grass pollen-allergic individuals, making it a key marker for genuine sensitization alongside Phl p 1. This small protein (approximately 29-38 kDa) features a unique structure with two domains forming a protease-resistant four-helix bundle, high alanine content (26 mol%), and multiple independent conformational IgE epitopes—up to four clusters—that explain its potent ability to trigger severe allergic symptoms like rhinitis and asthma. Isoforms such as Phl p 5a, Phl p 5b, Phl p 5.0101, and Phl p 5.0201 show structural variations, including differences in N- and C-terminal epitopes, leading to individual patient reactivity patterns and cross-reactivity with other Pooideae grasses. While not a therapeutic target like receptors or enzymes, Phl p 5 serves in diagnostics and allergen immunotherapy, with recombinant forms used to map epitopes and assess sensitization. Its high-density IgE recognition underscores challenges in desensitization therapies due to epitope diversity and histamine-releasing potency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pollen allergen Phl p 5 (Phl p 5).